GLA
RARE icon

Great Lakes Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Great Lakes Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,822
Closed -$430K – 844
2025
Q2 		$430K Sell
11,822
-1,489
-11% -$53.7K ﹤0.01% 640
2025
Q1 		$482K Sell
13,311
-177,818
-93% -$7.4M ﹤0.01% 615
2024
Q4 		$8.04M Sell
191,129
-8,124
-4% -$403K 0.07% 232
2024
Q3 		$11.1M Buy
199,253
+166,732
+513% +$8.49M 0.09% 191
2024
Q2 		$1.34M Buy
32,521
+6,296
+24% +$269K 0.01% 530
2024
Q1 		$1.22M Sell
26,225
-1,548
-6% -$73K 0.01% 527
2023
Q4 		$1.33M Sell
27,773
-27,674
-50% -$1.07M 0.01% 501
2023
Q3 		$1.98M Sell
55,447
-14,216
-20% -$563K 0.02% 457
2023
Q2 		$3.21M Sell
69,663
-49,555
-42% -$2.3M 0.03% 404
2023
Q1 		$4.78M Buy
+119,218
New +$5.12M 0.04% 375
2021
Q2 		– Sell
-149,020
Closed -$17M – 744
2021
Q1 		$17M Buy
149,020
+8,734
+6% +$1.19M 0.27% 120
2020
Q4 		$19.4M Buy
+140,286
New +$16.6M 0.35% 87

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Great Lakes Advisors's RARE Position: Q3 2025 in Review

Great Lakes Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 11,822 shares — an estimated $430K sold.

Great Lakes Advisors first reported a position in RARE in Q4 2020 and held it in 12 quarters. The position peaked at $19.4M in Q4 2020. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Great Lakes Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Great Lakes Advisors sold 11,822 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $430K.
  • Great Lakes Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 12 quarters.
  • Great Lakes Advisors's Ultragenyx Pharmaceutical position peaked at $19.4M in Q4 2020.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Great Lakes Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.